[Medical and surgical treatment of Parkinson's disease]

Presse Med. 2017 Mar;46(2 Pt 1):218-224. doi: 10.1016/j.lpm.2017.01.018. Epub 2017 Mar 6.
[Article in French]

Abstract

The treatment of Parkinson's disease is symptomatic with the use of dopaminergic medications: levodopa, dopaminergic agonists and enzymatic inhibitors. At the initial stage, the main goals are to improve the quality of life of patients and delay the onset of motor complications, using a combination of these therapies taking into account both clinical disability and tolerance of different treatments. At the stage of motor and non-motor fluctuations inhibitors of MAO-B and COMT are proposed; amantadine may limit moderate dyskinesias. At the stage of disabling fluctuations continuous dopaminergic strategy is discussed: deep brain stimulation of different targets, subcutaneous apomorphine pump and intra intestinal Duodopa® administration. The monitoring of side effects remains essential for an early adjustment of medications; mainly nausea, orthostatic hypotension, drowsiness and sleep attacks, dyskinesias and behavioral disorders (hallucinations, impulse control disorders). A care pathway published in 2014 by the HAS develops the management process of parkinsonism and its multidisciplinary outpatient.

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / therapeutic use*
  • Apomorphine / therapeutic use
  • Aromatic Amino Acid Decarboxylase Inhibitors / therapeutic use
  • Catechol O-Methyltransferase Inhibitors / therapeutic use
  • Combined Modality Therapy
  • Deep Brain Stimulation* / adverse effects
  • Deep Brain Stimulation* / methods
  • Disease Progression
  • Dopamine Agonists / therapeutic use
  • Foreign-Body Reaction / etiology
  • Humans
  • Intracranial Hemorrhages / etiology
  • Monoamine Oxidase Inhibitors / therapeutic use
  • Mood Disorders / etiology
  • Parkinson Disease / drug therapy
  • Parkinson Disease / therapy*
  • Patient Selection
  • Quality of Life

Substances

  • Antiparkinson Agents
  • Aromatic Amino Acid Decarboxylase Inhibitors
  • Catechol O-Methyltransferase Inhibitors
  • Dopamine Agonists
  • Monoamine Oxidase Inhibitors
  • Apomorphine